Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions
Kidney FailureRenal Failure
Interventions
DRUG

Erythropoietin zeta

The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.

DRUG

Placebo

Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.

Trial Locations (1)

221 85

Dept Thoracic Surgery, Anestesia and Intensive Care, SUS-Lund, Lund

All Listed Sponsors
lead

Region Skane

OTHER

NCT01423955 - Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery | Biotech Hunter | Biotech Hunter